“Unraveling the Legal Labyrinth: Can AI Revolutionize Pharma Without Copyright Catastrophes?”
Second, there is confusion around copyright applicability. Of life science professionals polled, 42% do not consider copyright before sharing or using third-party information with AI tools — a gap that could lead to infringement risks. Graeme King, VP and head of data & AI governance at Amino Data, adds that many organizations also do not consider confidentiality rules, particularly related to clinical trial reports and drug performance data.
Third and finally, lack of expertise remains a barrier, with only 40% of organizations reporting to have a dedicated team or expert focused on AI copyright compliance. Specialized knowledge on data licensing, text-mining rights, copyright, and IP legislation are becoming a must, but these skills are hard to acquire and competition for hiring experts is fierce.
